Form D · Pharmaceuticals

BRICKELL BIOTECH, INC.

Miami, FL · CIK 0001497233

Offering snapshot reported Feb 19, 2015 · SEC filing

Reported sold
$7.27M
Offering amount: $10M
Investors reported
30
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 4, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 19, 2015Initial$7,268,189No comparison30SEC filing
Aug 13, 2014Initial$2,214,600No comparison24SEC filing
Mar 7, 2013Initial$3,573,899No comparison26SEC filing
Jul 22, 2010Initial$6,199,987No comparison13SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-234312
Offering of shares of Series C Convertible Preferred Stock.

Source: Form D, filed Feb 19, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
George B. Abercrombie Director
David Angulo Executive
Charles J. Betlach, Ph.D. Executive
Richard C. Bulman, Jr. Executive
David E. Cohen Director
Gerard S. Coombs, Cpa Executive
Gerald S. Coombs, Cpa Executive
Bradley R. Goldman Director
Reginald L. Hardy Director, Executive
William D. Ju Director
Glenn Prestwich Director
Andrew Sklawer Executive
Charles W. Stiefel Director
Dennison T. Veru Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2600 Sw 3 Rd Avenue, Suite 350
Miami, FL, 33129